RIGEL: 30 job cuts, new fostamatinib-led strategy

It's been a difficult year for Rigel Pharmaceuticals and it just got tougher for 30 of the company's employees, since Rigel decided to restructure its operations after fostamatinib failed earlier this year in three Phase III rheumatoid arthritis clinical trials.